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We commend the recent CORP statement by Poole and Jones (1) where they advocate the use 
of a supramaximal bout to verify maximal oxygen uptake (V̇O2max) obtained during 
incremental exercise. The authors cite research that supports this approach, particularly in 
clinical populations, where exercise testing provides important prognostic information, such as 
individuals with cystic fibrosis (CF). 
However, subsequent correspondence from van Breda et al. (3) regarding the CORP statement 
raised a point worthy of discussion, as their final conclusion states that “‘short constant-work 
rate verification phase’ after the steep-ramp test…is, at least in a clinical setting, unrealistic 
and unethical in certain patient populations” (pp. 1370). We disagree with this statement, as 
evidence has consistently shown that a verification phase is crucial if clinicians are to have 
confidence in the determination of V̇O2max. For example, we (2) have shown that a further 
increase in V̇O2 can be elicited by performing supramaximal verification, which also improves 
test-retest reliability and eliminates dependence on inadequate secondary criteria (heart rate, 
respiratory exchange ratio, blood lactate etc.), in paediatric patients with CF. Our group has 
also been utilising such cardiopulmonary exercise testing (CPET) within applied clinical 
practice for over five years with both adults and children with chronic respiratory diseases, and 
it provides a key component of the annual review process. Since March 2015, upon the 
employment of a full-time, clinically trained, exercise technician, 110 CPETs have been 
undertaken with 74 patients in a single CF Centre. Our group has subsequently deployed this 
two-stage protocol in a further three CF Centres, and additional clinical teams in the United 
Kingdom are interested in adopting this CPET methodology.   
Given the prognostic value of V̇O2max in clinical groups, being able to discriminate between 
‘day-to-day variation’ and clinically meaningful changes, due to disease progression and/or 
therapeutic intervention, is essential. This supramaximal protocol is affordable, accepted by 
patients and most importantly, safe when performed correctly. In our laboratory, and clinic, no 
adverse events have been reported across a full range of patients with varying degrees of 
clinical severity.    
We agree with van Breda et al. (3) that “the concepts of aerobic/anaerobic and ventilatory 
thresholds encompass important clinical information”, as they indeed hold essential utility 
(both functional and potentially prognostic). However, it should be noted such parameters 
should be normalised to a percentage of V̇O2max, which is meaningful only when an accurate 
measurement is obtained.   
In clinical practice, tracking changes in aerobic capacity over time will only be meaningful if 
the most accurate methodology is used. It is for this very reason of accurately establishing 
V̇O2max (and with it the submaximal parameters of aerobic function) that our group and 
associated clinical teams fully support the methodological recommendation of utilising a 
supramaximal verification bouts as part of a CPET. Indeed, previous clinical studies have 
suggested their own conclusions may be limited by the lack of supramaximal verification 
testing, highlighting the need to heed the advice presented in the original CORP statement (1).  
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